此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

The Impact of a Daily Dietary Supplement on Glycemic Control in Individuals With Overweight or Obesity

2026年9月17日 更新者:Landon Deru、University of South Alabama

This clinical trial will evaluate the efficacy of Metabolic Master Pack over a 90-day intervention period. Sixty adults will be randomized to receive either Metabolic Master Pack or placebo. Participants will wear continuous glucose monitors throughout the study, complete repeated blood collections, undergo DEXA body composition assessments, and complete dietary records. Results will provide high-quality evidence regarding the product's effects on glucose regulation and metabolic health.

研究概览

详细说明

Participants will enroll in this randomized, double-blind, placebo-controlled, parallel-group trial in which they will consume the assigned intervention daily, 15 minutes before their largest meal. Continuous glucose monitoring will be used to characterize glucose responses under real-world conditions. Repeated blood draws will quantify changes in metabolic hormones and inflammatory biomarkers during three distinct standardized meal tests. These tests will take place at baseline, 45 days, and 90 days of supplementation. DEXA scans and anthropometric measurements, such as waist circumfrance, will assess body composition changes. Dietary recalls will be collected to evaluate behavioral changes and dietary adherence. Activity monitors will be used to assess physical activity and sleep patterns.

Assessments:

Visit 1 (Baseline) - morning visit

  • Informed consent
  • DEXA scan (fasted)
  • Waist and hip circumference
  • Placement of CGM #1

Visit 2 (Day 2) - morning visit

  • Fasted Standardized meal test
  • Pre-test blood draw, 30 minutes post blood draw, 1 hour post blood draw
  • During the resting/waiting period:
  • Give activity tracker and orient to dietary tracking. Ensure CGM functionality.

Visit 3 (Day 15)

  • Check symptoms and adverse events
  • Replace glucose monitor
  • Dietary tracking and physical activity education

Visit 4 (Day 30)

  • Check symptoms and adverse events
  • Replace glucose monitor
  • Dietary tracking and physical activity education

Visit 5 (Day 45- halfway point)

  • Fasted standardized meal and blood draws
  • Check symptoms and adverse events
  • Replace glucose monitor
  • Dietary tracking and physical activity education

Visit 6 (Day 60)

  • Check symptoms and adverse events
  • Replace glucose monitor
  • Dietary tracking and physical activity education

Visit 7 (Day 75)

  • Check symptoms and adverse events
  • Replace glucose monitor
  • Dietary tracking and physical activity education

Visit 8 (Day 90)

  • Fasted standardized meal and blood draws
  • Waist and hip circumference measurements
  • DEXA scan
  • Collect equipment and supplies back from participant

Visit 9 (Day 91)

• CGM removal (Full 24 hr after intervention)

STATISTICAL ANALYSIS PLAN

Primary Outcome:

Change in acute fasted glucose AUC at baseline, Day 45 and Day 90.

Primary Analysis:

Mixed-effects linear model with:

  • Fixed effects: group, time, group × time
  • Random effect: participant

Secondary Analyses:

  • Repeated-measures mixed models for hormones
  • Repeated-measures mixed models for body composition
  • ANCOVA models controlling for baseline values
  • Sensitivity analyses for dietary intake and adherence
  • Physical Activity data as a covariate with glucose data

Power Analysis:

Assuming an effect size of d=0.60, alpha=0.05, and 80% power, 52 participants are required. Enrollment of 60 participants allows for approximately 15% attrition.

研究类型

介入性

注册 (估计的)

60

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 65年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • BMI 25-40 kg/m²
  • Ability to provide informed consent

Exclusion Criteria:

  • Taking medications that impact metabolism
  • Report sustained weight loss of >3% in the past 3 months.
  • History of metabolic/bariatric surgery.
  • Females who are pregnant, have been pregnant within the past 6 months, or plan to become pregnant during the study period.
  • Report a current medical condition or treatment for a medical condition that could affect body weight or contradict engagement in any aspect of the outcome measures or interventions.
  • Current congestive heart failure, angina, uncontrolled arrhythmia, symptoms indicative of an increased acute risk for a cardiovascular event, prior myocardial infarction or history of cardiomyopathy, coronary artery bypass grafting or angioplasty, conditions requiring chronic anticoagulation (i.e., recent or recurrent DVT).
  • Resting systolic blood pressure of >160 mmHg or resting diastolic blood pressure of >100 mmHg. If medicated for blood pressure control, the medication dose needs to be stable for >6 months.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:支持治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Supplement

This group receives the supplement for 90 days

This trial will test the effectiveness of these unique compounds to improve postprandial glycemic excursion. This includes both long-term and acute control.

安慰剂比较:Placebo

This group receives the placebo for 90 days

This group will receive 90 days of a multivitamin placebo.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Interstitial Glucose
大体时间:Continuous glucose monitoring will take place over the course of the 90 day intervention

continuous glucose monitoring

Continuous glucose monitoring will take place over the course of the 90 day intervention
Blood Biomarkers
大体时间:Baseline (prior to any supplementation), then on day 45 of supplementation and on day 90 of supplementation. Each blood draw will be taken in the morning after an overnight fast and again 30 and 60 minutes after a standardized meal is consumed.

Insulin, Glucagon, GLP-1, Ghrelin, Leptin, and other metabolic biomarkers will be analyzed as part of an acute mixed-meal tolerance test.

Baseline (prior to any supplementation), then on day 45 of supplementation and on day 90 of supplementation. Each blood draw will be taken in the morning after an overnight fast and again 30 and 60 minutes after a standardized meal is consumed.

次要结果测量

结果测量
措施说明
大体时间
Body Composition
大体时间:Baseline and at the end of the intervention

Dual-energy X-ray Absorptiometry (DEXA) for assessment of body fat percentage, lean mass, and bone density.

Baseline and at the end of the intervention
Dietary Patterns
大体时间:5 dietary recalls over the 90 day intervention.

Random 24-hour dietary recall to assess changes in dietary patterns over the 90-day intervention.

5 dietary recalls over the 90 day intervention.
Participant Height
大体时间:At the baseline visit

Height to the nearest tenth of a centimeter will be recorded using a standard wall-mounted sadometer

At the baseline visit
Participant mass
大体时间:Baseline, Day 45 of intervention and day 90 of intervention

Participant mass will be measured using a standard scientific weight scale and recorded to the nearest tenth of a kilogram.

Baseline, Day 45 of intervention and day 90 of intervention
Waist circumfrence
大体时间:Baseline and at 45 days and 90 days of intervention.

Participants' waist circumferences will be measured using a standard flexible PVC measuring tape around the umbilicus and at the level of the iliac crest.

Baseline and at 45 days and 90 days of intervention.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年10月1日

初级完成 (估计的)

2027年9月1日

研究完成 (估计的)

2027年12月1日

研究注册日期

首次提交

2026年9月9日

首先提交符合 QC 标准的

2026年9月17日

首次发布 (实际的)

2026年9月24日

研究记录更新

最后更新发布 (实际的)

2026年9月24日

上次提交的符合 QC 标准的更新

2026年9月17日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • TBD-IRB in Progress

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅